In order to confirm that HER2 was expressed on tumor-infiltrated immune cells, and determine whether HER2 could be transferred to immune effector cells by trogocytosis, we isolated individual tumor cells from a HER2+ breast cancer patient treated with trastuzumab (N = 1) and a HER2− luminal type breast cancer patient. This evidence concerns the gene ERBB2 and breast cancer.